Literature DB >> 6339410

Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice.

F Bistoni, M Baccarini, E Blasi, P Marconi, P Puccetti, E Garaci.   

Abstract

Mice receiving a single injection of cyclophosphamide (150 mg/kg) 1 to 6 days before inoculation with viable Candida albicans showed an increased susceptibility to the challenge accompanied by a reduction in peripheral blood polymorphonuclear leukocytes and lymphocytes as well as in spleen cellularity. Several immunological in vitro functions also appeared to be dramatically depressed. Most of these hematological and functional parameters returned to control values by day 9 after cyclophosphamide administration, at a time when resistance to C. albicans infection appeared to be unchanged. However, when exposure to cyclophosphamide occurred 12 to 21 days before inoculation with the live yeast, enhanced resistance was observed with the majority of the animals surviving challenge. To gain some insight into the mechanisms underlying this late increase in resistance to C. albicans infection after cyclophosphamide administration, we analyzed a series of immunological functions, including the in vitro candidacidal activity of polymorphonuclear neutrophils and plastic-adherent and nonadherent spleen cells as well as the activity of natural killer cells and alloreactive T lymphocytes. The results show that a numerical rebound of blood polymorphonuclear neutrophils and the appearance of a highly candidacidal cell population in the spleen may be among the factors underlying the late increase in resistance to C. albicans after administration of cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339410      PMCID: PMC264816          DOI: 10.1128/iai.40.1.46-55.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Inducibility of germ-tube formation in Candida albicans at different phases of yeast growth.

Authors:  E Mattia; A Cassone
Journal:  J Gen Microbiol       Date:  1979-08

Review 2.  The immunopharmacology of cyclophosphamide.

Authors:  F L Shand
Journal:  Int J Immunopharmacol       Date:  1979

3.  In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans.

Authors:  J W Murphy; D O McDaniel
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

4.  Natural cell-mediated cytotoxicity against Trichomonas vaginalis in the mouse. I. Tissue, strain, age distribution, and some characteristics of the effector cells.

Authors:  S Landolfo; M G Martinotti; P Martinetto; G Forni
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

5.  Transplantation resistance of drug-treated hybrid or allogeneic mice against murine lymphomas. I. Immunopharmacology studies.

Authors:  A Bonmassar; C Riccardi; P Rivosecchi-Merletti; A Goldin; E Bonmassar
Journal:  Int J Cancer       Date:  1980-12-15       Impact factor: 7.396

6.  Increase of mouse resistance to Candida albicans infection by thymosin alpha 1.

Authors:  F Bistoni; P Marconi; L Frati; E Bonmassar; E Garaci
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

7.  Systemic candidiasis in mice. II.--Main role of polymorphonuclear leukocytes in resistance to infection.

Authors:  B Hurtrel; P H Lagrange; J C Michel
Journal:  Ann Immunol (Paris)       Date:  1980 Jan-Feb

8.  Identification and separation of Thy-1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Authors:  M J Mattes; S O Sharrow; R B Herberman; H T Holden
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

9.  Experimental vaccination with Candida albicans ribosomes in cyclophosphamide-treated animals.

Authors:  E Segal; H Sandovsky-Losica
Journal:  Sabouraudia       Date:  1981-12

10.  Effects of cyclophosphamide on murine candidiasis.

Authors:  S A Moser; J E Domer
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

View more
  24 in total

1.  Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice.

Authors:  E Cenci; L Romani; A Vecchiarelli; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

3.  Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans.

Authors:  G Samonis; N C Karyotakis; E J Anaissie; E Barbounakis; S Maraki; Y Tselentis; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Evidence for macrophage-mediated protection against lethal Candida albicans infection.

Authors:  F Bistoni; A Vecchiarelli; E Cenci; P Puccetti; P Marconi; A Cassone
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

5.  Host defence mechanisms, antibiotics and immunosuppressive agents--a complex relationship.

Authors:  T E Miller
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans.

Authors:  F Bistoni; A Vecchiarelli; R Mazzolla; P Puccetti; P Marconi; E Garaci
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans.

Authors:  G Arancia; A Molinari; P Crateri; A Stringaro; C Ramoni; M L Dupuis; M J Gomez; A Torosantucci; A Cassone
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Heterogeneous activity of immature and mature cells of the murine monocyte-macrophage lineage derived from different anatomical districts against yeast-phase Candida albicans.

Authors:  T Decker; M L Lohmann-Matthes; M Baccarini
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

Review 9.  An overview of macrophage-fungal interactions.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1986-02       Impact factor: 2.574

10.  In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative.

Authors:  M Kakushima; S Masuyoshi; M Hirano; M Shinoda; A Ohta; H Kamei; T Oki
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.